Results of Operations and Financial Condition. On July 29, 2026, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subj…

Other Events. On May 21, 2026, the Company announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (“FDA”). The updated Mint commercialization timeline expectation is based on the FDA’s initial responses to the Company’s Mint alternate controller enabled (“ACE”) insulin pump 510(k) application, and the progress the Company has made in scaling its Mint manufacturing processes. The C…

Results of Operations and Financial Condition. On April 21, 2026, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise sub…

Results of Operations and Financial Condition. On February 17, 2026, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Other Events. On January 29, 2026, Beta Bionics, Inc. (the “Company”) received a warning letter (the “Warning Letter”) from the U.S. Food and Drug Administration (the “FDA”) following inspection of the Company’s facility in Irvine, California that occurred from June 9, 2025 through June 26, 2025. In the Warning Letter, the FDA cited deficiencies in the response letters sent by the Company to the FDA following the FDA’s issuance of a Form 483, List of Investigational Observations (the “Form 48…

Results of Operations and Financial Condition. On January 8, 2026, Beta Bionics, Inc. (the “Company”) issued a press release announcing its preliminary, unaudited fourth quarter 2025 topline financial results and key metrics. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchang…

Results of Operations and Financial Condition. On October 28, 2025, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwi…

Results of Operations and Financial Condition. On July 29, 2025, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the for the second quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherw…

Other Events On June 22, 2025, the Company announced updated “Real-world” iLet Bionic Pancreas (“iLet”) data sourced from iLet users who uploaded continuous glucose monitor (“CGM”) readings to the Beta Bionics cloud over the first two years after the iLet’s commercial launch (May 19, 2023 to May 18, 2025). 16,439 iLet users uploaded at least three-weeks’ worth of iLet data. Of those 16,439 iLet users, 14,952 had a pre-iLet baseline HbA1c value available (as provided to us by the medical provi…

Results of Operations and Financial Condition. On May 6, 2025, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subjec…

Director — Gerard Michel: Gerard Michel was appointed as a Class III director of the Company.

Results of Operations and Financial Condition. On March 25, 2025, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Other Events. On January 31, 2025, the Company issued a press release announcing the closing of its IPO of 13,800,000 shares of its common stock, including 1,800,000 additional shares pursuant to the exercise in full by the underwriters of their option to purchase shares of common stock from the Company and the selling stockholders (consisting of 475,000 shares from the Company and 1,325,000 shares from the selling stockholders), at a price to the public of $17.00 per share. In addition to th…

Unregistered Sales of Equity Securities. On January 21, 2025, Beta Bionics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement with Wellington Hadley Harbor Aggregator IV, L.P. (the “Purchaser”), an existing stockholder of the Company, for the purchase of 1,000,000 shares of the Company’s common stock, par value $0.0001 (“Common Stock”), at a per share price equal to the IPO (as defined below) price of $17.00 per share, through a private placement financing (the “Private Plac…